Simplex Trading
ALLO icon

Simplex Trading’s Allogene Therapeutics ALLO Stock Holding History

Simplex Trading’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-53,282
Closed -$117K – 9202
2026
Q1 		$130K Buy
53,282
+47,149
+769% +$94.5K ﹤0.01% 4781
2025
Q4 		$8.4K Buy
6,133
+1,952
+47% +$2.58K ﹤0.01% 7097
2025
Q3 		$5K Sell
4,181
-12,848
-75% -$15.3K ﹤0.01% 8267
2025
Q2 		$19K Sell
17,029
-642
-4% -$853 ﹤0.01% 6794
2025
Q1 		$25K Sell
17,671
-50,640
-74% -$95.5K ﹤0.01% 6384
2024
Q4 		$145K Buy
68,311
+41,181
+152% +$102K ﹤0.01% 4817
2024
Q3 		$75K Buy
+27,130
New +$72.3K ﹤0.01% 5500
2024
Q1 		– Sell
-20,210
Closed -$84.3K – 8753
2023
Q4 		$64K Buy
+20,210
New +$57.3K ﹤0.01% 5840
2023
Q3 		– Sell
-7,821
Closed -$34.3K – 8558
2023
Q2 		$38K Sell
7,821
-105,528
-93% -$571K ﹤0.01% 6088
2023
Q1 		$559K Buy
+113,349
New +$727K ﹤0.01% 3146
2022
Q4 		– Sell
-2,050
Closed -$19K – 9106
2022
Q3 		$22K Buy
+2,050
New +$27.9K ﹤0.01% 7400
2022
Q1 		– Sell
-6,605
Closed -$68.8K – 10288
2021
Q4 		$98K Buy
6,605
+2,455
+59% +$43.3K ﹤0.01% 6270
2021
Q3 		$110K Sell
4,150
-200
-5% -$4.75K ﹤0.01% 6479
2021
Q2 		$113K Sell
4,350
-16,332
-79% -$466K ﹤0.01% 6547
2021
Q1 		$730K Buy
20,682
+19,959
+2,761% +$673K ﹤0.01% 2828
2020
Q4 		$18K Buy
+723
New +$23.6K ﹤0.01% 7021
2020
Q2 		– Sell
-2,109
Closed -$76.3K – 7521
2020
Q1 		$40K Buy
+2,109
New +$50.2K ﹤0.01% 5350
2019
Q3 		– Sell
-157
Closed -$4.47K – 7175
2019
Q2 		$4K Sell
157
-6,148
-98% -$171K ﹤0.01% 6509
2019
Q1 		$182K Buy
6,305
+6,188
+5,289% +$180K ﹤0.01% 3716
2018
Q4 		$3K Buy
+117
New +$3.11K ﹤0.01% 6387

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Simplex Trading's ALLO Position: Q2 2026 in Review

Simplex Trading sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 53,282 shares — an estimated $117K sold.

Simplex Trading first reported a position in ALLO in Q4 2018 and held it in 20 quarters. The position peaked at $730K in Q1 2021. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Simplex Trading reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Simplex Trading sold 53,282 Allogene Therapeutics shares in Q2 2026, an estimated $117K.
  • Simplex Trading first reported a position in Allogene Therapeutics in Q4 2018 and held it in 20 quarters.
  • Simplex Trading's Allogene Therapeutics position peaked at $730K in Q1 2021.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.